Document is current
Any future updates will be listed below
-
Authors
Lalanne, Jean-Benoît https://orcid.org/0000-0001-8753-0669
Huynh, Chau
Mich, John K. https://orcid.org/0000-0002-1626-1139
Hunker, Avery C. https://orcid.org/0000-0003-0508-3637
McDiarmid, Troy A. https://orcid.org/0000-0002-4893-9733
Kim, Haedong https://orcid.org/0000-0003-3589-0042
Levi, Boaz P. https://orcid.org/0000-0002-8346-872X
Ting, Jonathan T. https://orcid.org/0000-0001-8266-0392
Shendure, Jay https://orcid.org/0000-0002-1516-1865
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (R01HG010632)
U.S. Department of Health & Human Services | National Institutes of Health (UF1MH128339)
U.S. Department of Health & Human Services | National Institutes of Health (UF1MH128339)
Cancer Research Society (1155581)
Paul G. Allen Family Foundation
Gouvernement du Canada | Natural Sciences and Engineering Research Council of Canada (Banting Fellowship)
Washington Research Foundation
- License Information
-
More Information
Article History
Received: 20 December 2024
Accepted: 19 March 2026
First Online: 28 April 2026
Competing interests
: J.S. is a scientific advisory board member, consultant and/or cofounder of Prime Medicine, Guardant Health, Camp4 Therapeutics, Phase Genomics, Adaptive Biotechnologies, Sixth Street Capital, Pacific Biosciences, Somite AI and 10x Genomics. J.K.M. and B.P.L. are founders of EpiCure Therapeutics. The other authors declare no competing interests.
